ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: This is due to the PKC-induced differentiation associated with the down-regulation of BCR-ABL activity, which raises the possibility that CML-derived DC vaccines will be less effective in presenting leukemia-specific Ags[44].